Rachel Ochs-Ross - Concepedia

Author

Rachel Ochs-Ross

Janssen (United States)

Also Known As

Ochs-Ross R, R. Ochs-Ross, Rachel Ochs-Ross

Publications

652

Citations

H-Index

Concepts

All Affiliations

Janssen (United States)Janssen (Belgium)Yale University Neurocrine Biosciences (United States)University of Connecticut

About

Rachel Ochs-Ross is an author at Janssen (United States) specializing in psychiatry, medicine, and mental health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	46
2	Education	1	1	29
3	Public Health	1	1	29
4	Social Sciences	1	1	17
5	Pharmacology	1	1	17

Rachel Ochs-Ross

Publications

624

Citations

H-Index

Page 1

	Year	Citations
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3 Rachel Ochs-Ross, Ella Daly, Yun Zhang, American Journal of Geriatric Psychiatry	2019	453
Genome-wide association study and polygenic risk score analysis of esketamine treatment response Qingqin S. Li, Ewa Wajs, Rachel Ochs-Ross, Scientific Reports	2020	47
Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study Rachel Ochs-Ross, Ewa Wajs, Ella Daly, American Journal of Geriatric Psychiatry	2021	38
Autism: Comorbidities and Treatment Patterns in the Real World, a Retrospective Cohort Study Among Children, Adolescents and Adults Newly Diagnosed with Autism Azza Shoaib, M. Soledad Cepeda, Gayle Murray, Journal of Autism and Developmental Disorders EducationMental HealthAutism Spectrum DisorderNeurodiversityAutism	2021	29
<p>First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18</p> Julia C. Finkel, J. Goldberg, Ronald Rosenburg, Journal of Pain Research	2019	20
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies Richard L. Doty, Vanina Popova, Crystal Wylie, CNS Drugs	2021	20
S114. Efficacy and Safety of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression Rachel Ochs-Ross, Ella Daly, Yun Zhang, Biological Psychiatry Psychoactive DrugPsychiatryElderly PatientsIntranasal Esketamine PlusPsychotropic Medication	2018	17

Page 1